Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|August 22, 2020
Chemokine biology on immune checkpoint-targeted therapiesDiane Letourneur, François-Xavier Danlos, Aurélien MarabelleGenome Medicine|November 4, 2025
Genome instability and crosstalk with the immune responseRoman M Chabanon, François-Xavier Danlos, Kaissa Ouali, et al.Seminars in Cell & Developmental Biology|February 15, 2018
Plasmacytoid pre-dendritic cells (pDC): from molecular pathways to function and disease associationSolana Alculumbre, Salvatore Raieli, Caroline Hoffmann, et al.Melanoma Research|December 3, 2014
Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanomaFrançois-Xavier Danlos, Cécile Pagès, Jennifer Roux, et al.European Journal of Cancer (Oxford, England : 1990)|April 18, 2021
Applications of single-cell and bulk RNA sequencing in onco-immunologyMaria Kuksin, Daphné Morel, Marine Aglave, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2026
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging StrategiesCassio Murilo Hidalgo-Filho, Valentina Santo, Eleonora Gariazzo, et al.Chest|May 10, 2016
Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced MelanomaFrançois-Xavier Danlos, Cécile Pagès, Barouyr Baroudjian, et al.Clinical and Experimental Immunology|September 8, 2025
Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokinesMarie Naigeon, Samuel Bitoun, Matthieu Roulleaux Dugage, et al.Histopathology|August 6, 2025
Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 casesMohamed-Amine Bani, Peggy Dartigues, Ranya Soufan, et al.European Journal of Cancer (Oxford, England : 1990)|April 21, 2024
Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockersPierre-Louis Cariou, Cédric Pobel, Jean-Marie Michot, et al.Pageof 5